Literatur
- 1
Grundker C, Gunthert A R, Westphalen S, Emons G.
Biology of the gonadotropin-releasing hormone system in gynecological cancers.
Eur J Endocrinol.
2002;
146
1-14
- 2 Gründker C, Emons G.
GnRH in cancers of reproductive organs. Lunenfeld B GnRH Analogs in Human Reproduction. London; Taylor and Francis 2005:
16-28
- 3
Grundker C.
Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological
cancer therapy.
Eur J Endocrinol.
2000;
143
569-572
- 4
Günthert A R, Gründker C, Bongertz T, Nagy A, Schally A V, Emons G.
Induction of apoptosis by AN‐152, a cytotoxic analog of luteinizing hormone-releasing
hormone (LHRH), in LHRH‐R positive human breast cancer cells is independent of multidrug
resistance-1 (MDR‐1) system.
Breast Cancer Res Treat.
2004;
87
255-264
- 5
Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser H P. et al .
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN‐152 in
human ovarian and endometrial cancer cell lines.
Int J Oncol.
2000;
17
1063-1069
- 6
Krebs L J, Wang X, Pudavar H E, Bergey E J, Schally A V, Nagy A. et al .
Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone
analogue by epidermal growth factor.
Cancer Res.
2000;
60
4194-4199
- 7
Grundker C, Volker P, Griesinger F, Ramaswamy A, Nagy A, Schally A V. et al .
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN‐152
on human endometrial and ovarian cancers xenografted into nude mice.
Am J Obstet Gynecol.
2002;
187
528-537
- 8
Gunthert A R, Grundker C, Bongertz T, Nagy A, Schally A V, Emons G.
Induction of apoptosis by AN‐152, a cytotoxic analog of luteinizing hormone-releasing
hormone (LHRH), in LHRH‐R positive human breast cancer cells is independent of multidrug
resistance-1 (MDR‐1) system.
Breast Cancer Res Treat.
2004;
87
255-264
- 9
Gunthert A R, Grundker C, Bongertz T, Schlott T, Nagy A, Schally A V. et al .
Internalization of cytotoxic analog AN‐152 of luteinizing hormone-releasing hormone
induces apoptosis in human endometrial and ovarian cancer cell lines independent of
multidrug resistance-1 (MDR‐1) system.
Am J Obstet Gynecol.
2004;
191
1164-1172
- 10
Gründker C, Schulz K, Günthert A R, Emons G.
Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and
inhibits apoptosis in ovarian cancer cells.
J Clin Endocrinol Metab.
2000;
85
3815-3820
- 11
Gründker C, Huschmand Nia A, Emons G.
Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers.
Mol Cancer Ther.
2005;
4
225-231
- 12
Millar R P.
GnRHs and GnRH receptors.
Anim Reprod Sci.
2005;
88
5-28
- 13
White R B, Eisen J A, Kasten T L, Fernald R D.
Second gene for gonadotropin-releasing hormone in humans.
Proc Natl Acad Sci USA.
1998;
95
305-309
- 14
Urbanski H F, White R B, Fernald R D, Kohama S G, Garyfallou V T, Densmore V S.
Regional expression of mRNA encoding a second form of gonadotropin-releasing hormone
in the macaque brain.
Endocrinology.
1999;
140
1945-1948
- 15
Tensen C, Okuzawa K, Blomenrohr M, Rebers F, Leurs R, Bogerd J. et al .
Distinct efficacies for two endogenous ligands on a single cognate gonadoliberin receptor.
Eur J Biochem.
1997;
243
134-140
- 16
Blomenrohr M, Heding A, Sellar R, Leurs R, Bogerd J, Eidne K A. et al .
Pivotal role for the cytoplasmic carboxyl-terminal tail of a nonmammalian gonadotropin-releasing
hormone receptor in cell surface expression, ligand binding, and receptor phosphorylation
and internalization.
Mol Pharmacol.
1999;
56
1229-1237
- 17
Neill J D, Duck L W, Sellers J C, Musgrove L C.
A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates.
Biochem Biophys Res Commun.
2001;
282
1012-1018
- 18
Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B. et al .
A novel mammalian receptor for the evolutionarily conserved type II GnRH.
Proc Natl Acad Sci USA.
2001;
98
9636-9641
- 19
Millar R, Conklin D, Lofton-Day C, Hutchinson E, Troskie B, Illing N. et al .
A novel human GnRH receptor homolog gene: abundant and wide tissue distribution of
the antisense transcript.
J Endocrinol.
1999;
162
117-126
- 20
Millar R P.
GnRH II and type II GnRH receptors.
Trends Endocrinol Metab.
2003;
14
35-43
- 21
Grundker C, Gunthert A R, Millar R P, Emons G.
Expression of gonadotropin-releasing hormone II (GnRH‐II) receptor in human endometrial
and ovarian cancer cells and effects of GnRH‐II on tumor cell proliferation.
J Clin Endocrinol Metab.
2002;
87
1427-1430
- 22
Eicke N, Gunthert A R, Viereck V, Siebold D, Behe M, Becker T. et al .
GnRH‐II receptor-like antigenicity in human placenta and in cancers of the human reproductive
organs.
Eur J Endocrinol.
2005;
153
605-612
- 23
Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R. et al .
High affinity binding and direct antiproliferative effects of LHRH analogues in human
ovarian cancer cell lines.
Cancer Res.
1993;
53
5439-5446
- 24
Emons G, Schroder B, Ortmann O, Westphalen S, Schulz K D, Schally A V.
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing
hormone analogs in human endometrial cancer cell lines.
J Clin Endocrinol Metab.
1993;
77
1458-1464
- 25
Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B. et al .
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH‐II on human
endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
Eur J Endocrinol.
2004;
151
141-149
- 26
Eicke N, Gunthert A R, Emons G, Grundker C.
GnRH‐II agonist [D-Lys6]GnRH‐II inhibits the EGF-induced mitogenic signal transduction
in human endometrial and ovarian cancer cells.
Int J Oncol.
2006;
29)
1223-1229
- 27
Fister S, Gunthert A R, Emons G, Grundker C.
Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in
human endometrial and ovarian cancer cells in vitro and in vivo.
Cancer Res.
2007;
67
1750-1756
C. Gründker
Klinik für Gynäkologie und Geburtshilfe
Klinikum der Georg-August-Universität
Robert-Koch-Straße 40
37099 Göttingen
Email: grundker@med.uni-goettingen.de
